Skip to main content
Log in

A switch from syringe-and-needle to thermostable MAP flu vaccines may be cost saving in Australia

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

A switch from syringe-and-needle to thermostable MAP flu vaccines may be cost saving in Australia. PharmacoEcon Outcomes News 887, 1 (2021). https://doi.org/10.1007/s40274-021-08017-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-08017-3

Navigation